Current Pharmacological Practices in Severe COVID-19
Nation-wide Cross-sectional Survey on Current Pharmacological Practices in Severe COVID-19
1 other identifier
observational
1,055
1 country
1
Brief Summary
The investigators aim to understand the variation in pharmacological therapies for the management of severe coronavirus disease 2019 (COVID-19) in India and compare it to the recent available evidence. The ongoing pandemic of COVID-19 has proven to be the greatest medical emergency of recent times. The evidence on the therapeutics has evolved significantly in last few months after initial use of re-purposed drugs. The objective of this study is to understand the current practices in the management of adults severe COVID-19 in India.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 30, 2020
CompletedFirst Posted
Study publicly available on registry
December 31, 2020
CompletedStudy Start
First participant enrolled
January 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2021
CompletedFebruary 16, 2021
February 1, 2021
14 days
December 30, 2020
February 13, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Choice and indication of pharmacological agents for management of Severe COVID-19
Cross-sectional survey will capture the current choice and indication of different pharmacological agents for management of Severe COVID-19 among participating physicians in India
two weeks
Interventions
Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
Eligibility Criteria
Physicians involved in the clinical management of adult severe COVID-19 patients in India.
You may qualify if:
- Physicians who are involved in management of adult patients with severe COVID-19 in India
You may not qualify if:
- Pediatrician Physicians who are not managing severe COVID-19 patients or refused to participate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Reliance Hospital
Mumbai, Mumbai, Mahrastra, India
Related Publications (2)
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
PMID: 32091533RESULTBerlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020 Dec 17;383(25):2451-2460. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15. No abstract available.
PMID: 32412710RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Prashant Nasa, MD EDICM
NMC Specialty Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Specialist Critical Care Medicine
Study Record Dates
First Submitted
December 30, 2020
First Posted
December 31, 2020
Study Start
January 4, 2021
Primary Completion
January 18, 2021
Study Completion
January 31, 2021
Last Updated
February 16, 2021
Record last verified: 2021-02